Germany · Delayed Price · Currency is EUR Akebia Therapeutics Company Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2007 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 181 |
| CEO | John Butler |
Contact Details
Address: 245 First Street Cambridge, Delaware 02142 United States | |
| Phone | 617 871 2098 |
| Website | akebia.com |
Stock Details
| Ticker Symbol | AX9 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| John Butler | Chief Executive Officer |
| Erik Ostrowski | Chief Financial Officer |
| Mercedes Carrasco | Head of Investor Relations |